The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. HSK31858 given as 20 mg or 40 mg performed better than ...
MADISON, Wis.--(BUSINESS WIRE)--Research published in Science reveals a new target for non-hormonal male contraception. The protein, a kinase called STK33, has been linked to infertility in male mice ...
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback